Results 211 to 220 of about 3,025,562 (306)

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

GeNePi: a graphics processing unit enhanced next-generation bioinformatics pipeline for whole-genome sequencing analysis. [PDF]

Brief Bioinform
Marangoni S, Furia F, Charrance D, Fant A, Di Dio S, Trova S, Spirito G, Musacchia F, Coppe A, Gustincich S, Vecchi M, Landuzzi F, Cavalli A.   +12 more
europepmc   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

MITE: the Minimum Information about a Tailoring Enzyme database for capturing specialized metabolite biosynthesis. [PDF]

Nucleic Acids Res
Rutz A, Probst D, Aguilar C, Akiyama DY, Alberti F, Augustijn HE, Avalon NE, Beemelmanns C, Barbieri HB, Biermann F, Bridge AJ, Girón EC, Cox R, Crüsemann M, D'Agostino PM, Feuermann M, Gerke J, García KG, Holme JE, Hwang JY, Iacovelli R, Jeronimo Barbosa JC, Kaur N, Klapper M, Köhler AM, Korenskaia A, Kubach N, Lee BT, Loureiro C, Mantri S, Narula S, Meijer D, Navarro-Muñoz JC, Nguyen GS, Paliyal S, Panghal M, Rao L, Sieber S, Sokolova N, Sowa ST, Szenei J, Terlouw BR, Weddeling HG, Yu J, Ziemert N, Weber T, Blin K, van der Hooft JJJ, Medema MH, Zdouc MM.   +49 more
europepmc   +1 more source

Strem Chemicals Inc commercialises catalysts designed by the Catalan Chemical Research Institute of Tarragona

Focus on Catalysts, 2013
openaire   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

A study on long-term trauma-related mental health outcomes among Kurdish survivors of chemical attacks. [PDF]

Front Psychiatry
Mohammed I, Ahmed H, Hasin B, Kizilhan J, Nariman H, Ahmed S, Qader A, Papiol S, Rubekeil M, Schulze T, Heilbronner U, Hautzinger M.   +11 more
europepmc   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source

Unhooking the Hook: Optimization of the Aurora A Targeting PROTAC <b>JB170</b> to <b>CCT400028</b>, an <i>In Vitro</i> Degrader Chemical Probe. [PDF]

J Med Chem
O'Hanlon JA, Gutsche K, Müller JE, Ranjan Prusty N, Mirza A, Roumeliotis TI, Yang H, Stubbs M, Hallett ST, Eing L, McAndrew PC, Choudhary JS, Le Bihan YV, Caldwell J, van Montfort RLM, Workman P, Wolf E, Newton GK, Evans LE.   +18 more
europepmc   +1 more source